Form 4: Benitec Biopharma Grants Stock Options to Executive

Benitec Biopharma Inc. granted stock options to Peter Francis, exercisable for 35,000 shares of common stock, vesting no later than December 9, 2025.

Summary

• Benitec Biopharma Inc. has granted stock options to Peter Francis.
• These options allow the purchase of 35,000 shares of common stock at an exercise price of $12.18 per share.
• The options vest on the earlier of the company's next annual stockholders' meeting or December 9, 2025.

Sentiment

Score: 7

Explanation: The document reflects a standard corporate practice of granting stock options, which is generally viewed positively as it aligns management and shareholder interests. There are no indications of negative sentiment.

Positives

• The granting of stock options can serve as an incentive for Peter Francis to contribute to the company's success.
• The vesting schedule aligns the executive's interests with those of the shareholders.

Risks

• The value of the stock options is dependent on the future performance of Benitec Biopharma's stock price.
• If the stock price does not increase above the exercise price, the options may not be valuable to the recipient.

Future Outlook

The vesting of the stock options is contingent on the company's next annual stockholders' meeting or December 9, 2025, whichever comes first.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard practice in the biotech industry to incentivize executives.
• The vesting period of approximately one year is typical for such grants.
• The exercise price is set at the market price at the time of the grant, which is a common practice.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes management.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Next Steps

• The stock options will vest upon the earlier of the company's next annual stockholders' meeting or December 9, 2025.

Key Dates

Keywords

stock options, equity compensation, executive compensation, vesting, Benitec Biopharma, BNTC